This review is an attempt to bring together the pharmacokinetic data on d-tubocurarine and pancuronium with clinical observations on relaxant dosage and effect. The modelling techniques used here represent an oversimplification of the relationships between relaxant plasma concentration and response as they do not predict either the time of onset of paralysis or its peak intensity. However, they do enable calculation of a bolus dose of relaxant required to achieve a particular intensity of paralysis for the average patient once pseudo-distribution equilibrium has been achieved. This has been further extended to predict the cumulation of the relaxants with subsequent dosage in average patients.
Suggested regimens incorporating bolus and infusion doses of the relaxants to achieve continuous neuromuscular blockade have been calculated also.
Averaged pharmacokinetic parameters derived from patients with renal or hepatic dysfunction have been used to predict the likely duration and intensities of paralysis for the relaxants.
SomogyiA.A., ShanksC.A., TriggsE.J.Concentration-response curves for pancuronium in man. Abstracts 5th Eur Congr Anaesth 1978; 212.
7.
SomogyiA.A., ShanksC.A., TriggsE.J.Combined IV bolus and infusion of pancuronium bromide.Br J Anaesth1978; 50: 575–582.
8.
RamzanM.I., ShanksC.A., TriggsE.J.Studies of d-tubocurarine pharmacokinetics in humans and dogs.Anaesth Intens Care1978; 6: 30–35.
9.
RamzanM.I., ShanksC.A., TriggsE.J.The pharmacokinetics of d-tubocurarine administered by combined IV bolus and infusion.Br J Anaesth1979; (in press).
10.
ShanksC.A., RamzanM.I., TriggsE.J.Studies in man with a constant-rate IV infusion of tubocurarine.Anaesth Intens Care1979; 7: 209–214.
11.
MillerR.D., EgerE.I.Early and late relative potencies of pancuronium and d-tubocurarine in man.Anesthesiology1976; 44: 297–300.
12.
MillerR.D., WayW.L., DolanW.M., StevensW.C., EgerE.I.Comparative neuromuscular effects of pancuronium, gallamine and succinylcholine during forane and halothane anesthesia in man.Anesthesiology1971; 35: 509–514.
13.
WaudB.E., WaudD.R.The relation between tetanic fade and receptor occlusion in the presence of competitive neuromuscular block.Anesthesiology1971; 35: 456–464.
14.
WaudB.E., WaudD.R.The relation between the response to “train-of-four” stimulation and receptor occlusion during competitive neuromuscular block.Anesthesiology1972; 37: 413–416.
15.
WaudB.E., WaudD.R.The margin of safety of neuromuscular transmission in the muscle of the diaphragm.Anesthesiology1972; 37: 417–422.
16.
ShanksC.A., SomogyiA.A., TriggsE.J.Dose-response and plasma concentration response relationships of pancuronium in man.Anesthesiology1979; 51: 111–118.
17.
HullC.J., Van BeemH.B.H., McLeodK., SibbaldA., WatsonM.J.A pharmacodynamic model for pancuronium.Br J Anaesth1978; 50: 1113–1123.
18.
SheinerL.B., StanskiD.R., VozehS., MillerR.D., HamJ.Simultaneous modelling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.Clin Pharmacol Ther1979; 25: 358–371.
19.
MatteoR.S., SpectorS., HorowitzP.E.Relation of serum d-tubocurarine concentrations to neuromuscular block in man.Anesthesiology1974; 41: 440–443.
20.
FeldmanS.A.Serum dTC and neuromuscular blockade in man.Anesthesiology1975; 42: 644–645.
21.
WaudB.E.Serum d-tubocurarine concentration and twitch height.Anesthesiology1975; 43: 381.
22.
KatzR.L.Neuromuscular effects of d-tubocurarine, edrophonium and neostigmine in man.Anesthesiology1967; 28: 327–336.
23.
PatonW.D.M., WaudD.R.The margin of safety of neuromuscular transmission.J Physiol1967; 191: 59–90.
24.
WaudB.E., WaudD.R.Physiology and pharmacology of neuromuscular blocking agents. In: KatzRL. ed., Muscle Relaxants.North-Holland Publishing Co.1975; 1–58.
25.
GhoneimM.M., KramerE., BannowR., PandyaH., RouthJ.I.Binding of d-tubocurarine to plasma proteins in normal man and in patients with hepatic or renal disease.Anesthesiology1973; 39: 410–415.
26.
WaserP.G.Localization of 14C-pancuronium by histo- and wholebody-autoradiography in normal and pregnant mice.NS Arch Pharm1973; 279: 399–412.
27.
ThompsonJ.M.Pancuronium binding by serum proteins.Anaesthesia1976; 31: 219–227.
28.
LevyG.Relationship between rate of elimination of tubocurarine and rate of decline of its pharmacological activity.Br J Anaesth.1964; 36: 694–5.
29.
GibaldiM., LevyG.Dose-dependent decline of pharmacologic effects of drugs with linear pharmacokinetic characteristics.J Pharm Sci1972; 61: 567–569.
30.
DonlonJ.V., AliH.H., SavareseJ.J.A new approach to the study of four nondepolarizing relaxants in man.Anesth Analg1974; 53: 934–939.
LundI., StovnerJ.Dose-response curves for tubocurarine, alcuronium and pancuronium.Acta Anaesth Scand Suppl1970; 37: 238–242.
33.
RyanA.R.Tubocurarine administration based upon its disappearance and accumulation curves in anaesthetized man.Br J Anaesth1964; 36: 287–294.
34.
KatzR.L.Clinical neuromuscular pharmacology of pancuronium.Anesthesiology1971; 34: 550–556.
35.
d'HollanderA.A., CamuF., SandersM.Comparative evaluation of neuromuscular blockade after pancuronium administration in patients with and without renal failure.Acta Anaesth Scand1978; 22: 21–26.
MillerR.D., MatteoR.S., BenetL.Z., SohnY.J.The pharmacokinetics of d-tubocurarine in man with and without renal failure.J Pharm Exper Ther1977; 202: 1–7.
38.
SomogyiA.A., ShanksC.A., TriggsE.J.Disposition kinetics of pancuronium bromide in patients with total biliary obstruction.Br J Anaesth1977; 49: 1103–1108.
39.
Dal SantoG.Kinetics of distribution of radioactive labelled muscle relaxants. Investigation with C14-dimethyl-d-tubocurarine.Anesthesiology1964; 25: 788–800.
40.
DuvaldestinP., AgostonS., HenzelD., KerstenU.W., DesmontsJ.M.Pancuronium pharmacokinetics in patients with liver cirrhosis.Br J Anaesth.1978; 50: 1131–1136.
41.
McLeodK., WatsonM.J., RawlinsM.D.Pharmacokinetics of pancuronium in patients with normal and impaired renal function.Br J Anaesth1976; 48: 341–345.
42.
SomogyiA.A., ShanksC.A., TriggsE.J.The effect of renal failure on the disposition and neuromuscular blocking action of pancuronium bromide.Eur J Clin Pharmacol1977; 12: 23–29.
43.
OliveroJ.P., DuvaldestinP., HenzelD., GuyP., GlaserP.Pharmacokinetics of pancuronium during continuous infusion in patients with acute renal failure.Abstracts 5th Eur Congr Anesth1978; p. 101.
44.
MillerR.D., StevensW.C., WayW.C.The effect of renal failure and hyperkalaemia on the duration of pancuronium neuromuscular blockade in man.Anesth Analg1973; 52: 661–666.
45.
AgostonS., CrulJ.F., KerstenU.W., ScafA.H.J.Relationship of the serum concentration of pancuronium to its neuromuscular activity in man.Anesthesiology1977; 47: 509–512.
46.
WaudB.E., ChengM.C., WaudD.R.Comparison of drug-receptor dissociation constants at the mammalion neuromuscular junction in the presence and absence of halothane.J Pharmacol Exp Ther1973; 187: 40–46.
47.
GibaldiM., LevyG., WeintraubH.Drug distribution and pharmacologic effects.Clin Pharmacol Ther1971; 12: 734.
